Wall Street Zen Upgrades Septerna (NASDAQ:SEPN) to Buy

Septerna (NASDAQ:SEPN) was upgraded by Wall Street Zen from a “sell” rating to a “buy” rating in a research note issued to investors on Sunday.

A number of other analysts have also issued reports on SEPN. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Septerna in a report on Friday, September 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. HC Wainwright raised their price objective on shares of Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Finally, Wells Fargo & Company raised shares of Septerna from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $18.00 to $28.00 in a research report on Friday. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.25.

Septerna Price Performance

Septerna stock opened at $21.64 on Friday. The firm has a market cap of $968.82 million and a price-to-earnings ratio of -14.33. Septerna has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The firm has a fifty day moving average price of $19.48 and a two-hundred day moving average price of $13.96.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.28). The business had revenue of $21.50 million during the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. As a group, sell-side analysts expect that Septerna will post -7.11 earnings per share for the current year.

Insider Activity at Septerna

In other news, SVP Daniel D. Long sold 3,501 shares of Septerna stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $18.06, for a total transaction of $63,228.06. Following the sale, the senior vice president owned 92,911 shares of the company’s stock, valued at approximately $1,677,972.66. This trade represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SEPN. KLP Kapitalforvaltning AS bought a new position in Septerna in the first quarter worth $49,000. XTX Topco Ltd acquired a new position in shares of Septerna in the 1st quarter valued at $216,000. Chicago Partners Investment Group LLC acquired a new position in shares of Septerna in the 1st quarter valued at $63,000. TRV GP VI LLC lifted its holdings in shares of Septerna by 33.6% during the 1st quarter. TRV GP VI LLC now owns 4,211,659 shares of the company’s stock worth $24,386,000 after acquiring an additional 1,059,203 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Septerna by 53.3% during the 1st quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock valued at $92,000 after acquiring an additional 5,549 shares in the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.